相关实验视频

Updated: Jan 9, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

葡萄糖类-1受体激活剂对代谢功能障碍相关的脂肪肝炎患者的影响:系统性审查和顺序元分析的协议

Mei-Jun Wang¹, Yu-Nuo Jiang¹, Pei-Pei Li²

¹Anhui University of Chinese Medicine, Hefei, China.

Systematic reviews

|December 10, 2025

概括

本系统性审查评估了类似葡萄糖-1受体激动剂 (GLP-1RA) 用于治疗与代谢功能障碍相关的脂肪肝炎 (MASH). 它旨在澄清GLP-1RA在MASH患者中的疗效和安全性.

科学领域:

肝病学和胃肠道学
药理学和药物发现
代谢和内分泌疾病代谢和内分泌疾病

背景情况:

代谢功能障碍相关的脂肪肝炎 (MASH) 是与肥胖和代谢综合征相关的日益严重的全球健康问题.
类似葡萄糖-1受体激动剂 (GLP-1RA) 由于其代谢和抗炎作用,对MASH治疗具有前景.
现有的关于MASHGLP-1RA的临床数据因异质性和短期随访而受到限制.

研究的目的:

系统地审查和元分析GLP-1RA在活检确认MASH中的随机对照试验 (RCT).
评估GLP-1RA的组织学疗效 (MASH解决,纤维化改善) 和安全性.
为MASH管理提供GLP-1RA的强有力的基于证据的评估.

主要方法:

在MASH患者中,对RLT进行系统审查和元分析,将GLP-1RA与安慰剂进行比较.
在主要数据库 (PubMed,科学网,Embase,柯克伦图书馆) 进行全面的文献搜索.
严格的数据提取,偏差风险评估 (Cochrane ROB 2),元分析 (随机效应模型),元回归和试验顺序分析 (TSA).

主要成果:

主要结局包括MASH解消而没有纤维化恶化和纤维化改善而没有MASH恶化.
二次结果将评估生理和生化参数.
该审查将使用GRADE证据确定性框架量化GLP-1RA的疗效和安全性.

结论:

本系统性审查协议旨在提供高确定性证据,证明GLP-1RA对MASH的有效性.
这些发现将为临床实践和MASH治疗的未来研究方向提供信息.
这项研究将解决有关MASH的长期GLP-1RA疗效的当前知识的关键差距.

关键词:

在GLP-1 RAs中.葡萄糖样-1受体激动剂的葡萄糖样-1受体激动剂进行元分析分析.与代谢功能障碍相关的脂肪肝炎.

更多相关视频

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Acute Pancreatitis II: Clinical Manifestations and Management

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...